Castle Biosciences' AdvanceAD-Tx Test Validates Faster, Deeper Responses in Atopic Dermatitis
Event summary
- Castle Biosciences' AdvanceAD-Tx test identified 30% of moderate-to-severe atopic dermatitis patients as JAK Inhibitor Responders, who achieved 5.5x higher EASI-90 improvement with JAK inhibitors vs. Th2-targeted therapies.
- JAK Inhibitor Responder Profile patients treated with JAK inhibitors showed 4x faster response, 36.4% near-complete skin clearance, and 45.5% reporting no itch by three months.
- Th2 Molecular Profile patients showed no significant differences between JAK inhibitors and Th2-targeted therapies, supporting shared decision-making.
- Study published in JAAD on February 19, 2026, following AdvanceAD-Tx's limited commercial launch in late 2025.
The big picture
Castle Biosciences' validation study positions AdvanceAD-Tx as a key player in precision dermatology, aligning with the broader trend toward molecularly guided treatment decisions. The test's ability to identify JAK Inhibitor Responders could streamline care and improve outcomes in a market increasingly focused on personalized medicine. With atopic dermatitis affecting millions globally, the strategic implications for patient care and diagnostic market share are significant.
What we're watching
- Adoption Pace
- How quickly clinicians will integrate AdvanceAD-Tx into treatment plans for moderate-to-severe atopic dermatitis patients.
- Market Differentiation
- Whether Castle Biosciences can sustain competitive advantage as other diagnostics enter the personalized dermatology space.
- Reimbursement Dynamics
- The pace at which payers will cover AdvanceAD-Tx, given its potential to reduce treatment changes and accelerate improvement.
Related topics